Bio-Techne (NASDAQ:TECH), a life science reagents, instruments, and bioprocessing tools provider, closed at $70.67, up 20.02%. Merck KGaA’s $73-per-share cash offer drove the move, and investors are watching the deal timetable and any updates on closing conditions. Trading volume reached 51.3M shares, coming in about 1,378% above its three-month average of 3.5M shares.
How the markets moved today
The S&P 500 (SNPINDEX:^GSPC) finished at 7,357, down 0.01%, while the Nasdaq Composite (NASDAQINDEX:^IXIC) closed at 25,359, down 0.46%. Among life sciences tools, reagents, instruments, and diagnostics/bioprocessing services peers, Danaher closed at $193.23, up 2.31%, and Repligen closed at $145.23, up 4.93%.
What this means for investors
One week after it was reported that activist investor Ananym Capital Management had built a stake in Bio-Techne and announced it would be pushing for the company to be sold, a $73-per-share deal from Merck KGaA came in, sending shares soaring. With TECH stock now near $71, it seems the market is optimistic the deal will go through, at a time when $419 billion in healthcare deals have already been completed in 2026 — the most since 2021.
Profitable and growing sales by 10% annually over the last decade, Bio-Techne will help reload Merck KGaA’s pipeline, adding “complementary strengths across research, bioprocessing, and advanced therapeutics.” The $70 billion acquirer believes it will achieve annualized cost synergies of over $150 million within three years, adding roughly 5% to its bottom line, based on last year’s net income of roughly $3 billion.
Should you buy stock in Bio-Techne right now?
Before you buy stock in Bio-Techne, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Bio-Techne wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004… if you invested $1,000 at the time of our recommendation, you’d have $387,428!* Or when Nvidia made this list on April 15, 2005… if you invested $1,000 at the time of our recommendation, you’d have $1,221,398!*
Now, it’s worth noting Stock Advisor’s total average return is 895% — a market-crushing outperformance compared to 205% for the S&P 500. Don’t miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
